Safety and Tolerability, and PK of Sibeprenlimab in Chinese Healthy Subject

NCT07105124 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy Subjects (HS)

Interventions

DRUG: Sibeprenlimab

Sponsor

Otsuka Beijing Research Institute

Collaborators

[object Object]